Where Will CTI BioPharma Corp (CTIC) Stock Go Next After It Is Up 0.90% in a Week?

Tuesday, May 23, 2023 11:20 AM | InvestorsObserver Analysts

Mentioned in this article

Where Will CTI BioPharma Corp (CTIC) Stock Go Next After It Is Up 0.90% in a Week?

Overall market sentiment has been high on CTI BioPharma Corp (CTIC) stock lately. CTIC receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

CTI BioPharma Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CTIC!

See Full CTIC Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With CTIC Stock Today?

CTI BioPharma Corp (CTIC) stock is up 0.73% while the S&P 500 is lower by -0.26% as of 11:20 AM on Tuesday, May 23. CTIC has risen $0.06 from the previous closing price of $8.93 on volume of 1,782,074 shares. Over the past year the S&P 500 has gained 5.24% while CTIC has risen 76.27%. CTIC lost -$0.58 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for CTI BioPharma Corp click here.

More About CTI BioPharma Corp

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under pipeline include PIXUVRI, and Pacritinib. PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis. Click Here to get the full Stock Report for CTI BioPharma Corp stock.